[|1231] Sodium Iodide Ge Healthcare

Sodium Iodide (123 I) is a radiopharmaceutical used in diagnostic imaging for thyroid disorders. This sterile solution is administered intravenously for nuclear medicine scans. Suitable for patients requiring thyroid function evaluation or cancer detection. Short half-life ensures minimal radiation exposure.

Sodium Iodide (123 I) is primarily used for diagnostic imaging of the thyroid gland. It helps assess thyroid function, detect nodules, and identify thyroid cancer. The radiopharmaceutical is also used in whole-body scans to locate metastatic thyroid cancer. Patients undergoing thyroidectomy may receive this agent to evaluate residual tissue.

After intravenous administration, Sodium Iodide (123 I) is absorbed by the thyroid gland, emitting gamma radiation detectable by imaging equipment. The solution enables clear visualization of thyroid tissue and potential abnormalities. Patients may experience temporary mild discomfort at the injection site. Imaging results typically appear within hours, aiding in accurate diagnosis.

Sodium Iodide (123 I) should only be handled by trained medical professionals in controlled settings. Pregnant or breastfeeding individuals should avoid exposure due to radiation risks. Patients must disclose allergies, especially to iodine or shellfish. Hydration before and after administration may help reduce radiation exposure to the bladder.

Certain medications, such as thyroid hormones or antithyroid drugs, may interfere with Sodium Iodide (123 I) imaging results. Contrast agents used in CT scans can also affect thyroid uptake. Patients should inform their healthcare provider about all medications, supplements, or recent iodine exposure. Alcohol and specific foods may be restricted before the procedure.